Clinical Study
High Dose of Lamivudine and Resistance in Patients with Chronic Hepatitis B
Table 3
Treatment (biochemical and virological response).
| | | 12 months | 24 months | 36 months | 48 months | 60 Months |
| | HBV DNA IU/mL Below detection level | 35/40
(87.5%) | 31/40
(77.4%) | 25/40
(62.5%) | 20/40
(50%) | 16/40
(40%) | | Biochemical activity (high ALT) | 2/40 | normal | normal | normal | normal | | HBsAg seroconversion | 0% | 0% | 0% | 0% | 0% | | HBeAg seroconversion | 0% | 0% | 1 | 2 | 3 | | Viral breakthrough | 5/40
(12.5%) | 9/40
(22.5%) | 15/40
(37.5%) | 20/40
(50%) | 24/40
(60%) |
|
|
